IN THE SUPREME COURT OF THE STATE OF NEVADA

ZANE M. FLOYD, *Appellant*, vs. **CARDINAL HEALTH, INC., ET AL.**, *Respondents*.	No.: **85826**	Electronically Filed Mar 04 2024 04:28 PM Elizabeth A. Brown Clerk of Supreme Court

APPELLANT'S REPLY TO CARDINAL HEALTH'S RESPONSE TO MOTION FOR LEAVE TO FILE REQUEST TO TAKE JUDICIAL NOTICE

Marian L. Massey
Nevada State Bar No. 14579
TALG, NV, Ltd.
5852 S. Durango Drive
Suite 105
Las Vegas, Nevada 89113
(702) 954-3861
mmassey@talglaw.com

Counsel for Appellant Zane M. Floyd

Appellant Zane M. Floyd ("Appellant"), by and through his *pro bono* appellate counsel of record, Marian L. Massey, hereby submits this Reply to Cardinal Health's Response to Motion for Leave to File Request to Take Judicial Notice (the "Reply"). NDOC did not file a response to the Motion for Leave to File Request to Take Judicial Notice.

MEMORANDUM OF POINTS AND AUTHORITIES

Appellant's Motion for Leave to File a Request for Judicial Notice involves a straightforward request: if the Court is inclined to consider the issue of mootness based upon representations that the drugs purchased for use in his execution have expired, Mr. Floyd respectfully requests the Court to take judicial notice of a Status Report filed in his 42 U.S.C. § 1983 case regarding NDOC's recent purchase of execution drugs.

As an initial matter, because the issue of mootness was not properly raised in the record below and was not evaluated by the District Court, this Court may decline to consider mootness for the first time on appeal.[1]

[1] Cardinal Health's only discussion of the issue of mootness was raised in a footnote contained in its Reply in Support of the Motion to Dismiss and asserted the expiration of a single drug rendered Appellant's injunctive relief claim moot. *See* R 155 at n.6; *see* CH Ans. Br. 36–37; *but see* CH Resp. to Mot., at 1 (asserting Mr. Floyd seeks declaratory and injunctive relief).

Potasi v. Palomino Club, 498 P.3d 1283 (Nev. 2021) (Cadish, J.) (unpublished disposition) (citing *Edwards v. Emperor's Garden Rest.*, 122 Nev. 317, 330 n.38, 130 P.3d 1280, 1288 n.38 (2006)) (finding discussions relegated to a footnote that are "largely unsupported by record cites or legal authority" do not preserve issues for appeal). Given briefing has been completed, argument has been held, and the issues have been submitted for determination, this Court may decline to address those arguments. *Sargeant v. Henderson Taxi*, 133 Nev. 196, 199, 394 P.3d 1215, 1218 (2017) (declining to resolve appeal on the issue of mootness because "neither side addressed mootness in their briefs, so resolving this appeal on that basis would likely require supplemental briefing and consequent delay").

Nevertheless, if this Court is inclined to address the issue of mootness,[2] Mr. Floyd requests that the Court take judicial notice of the

[2] Cardinal Health asserts that mootness impacts the justiciability of certain claims, and thus appears to concede standing also impacts justiciability. *See* CH Resp. to Mot. at 1; *U.S. Parole Comm'n v. Geraghty*, 445 U.S. 388, 397 (1980) (finding mootness is "'the doctrine of standing in a time frame. The requisite personal interest must exist at the commencement of litigation (standing) must continue throughout its existence (mootness)"); *see Justiciable*, BLACK'S LAW DICTIONARY (11th ed. 2019) (defining a "justiciable" issue as being "subject to proper resolution

Status Report filed in his § 1983 case demonstrating NDOC recently purchased additional drugs for use in his execution. *See* CH Resp. to Mot., at 1. Cardinal Health does not appear to dispute this Court should take judicial notice of proceedings in Mr. Floyd's other case, and relies upon documents from *that very same case* to argue Appellant's claims in this case are moot. *See* CH Resp. to Mot., at 2 (referencing **Exhibits A, B,** and **C**). Thus, Cardinal Health apparently concedes this Court should take judicial notice of the documents from Mr. Floyd's § 1983 action.

Rather than explain why the Status Report is "not relevant or necessary to decide this appeal," Cardinal Health instead raises several new arguments regarding the mootness of Mr. Floyd's claims. *See* CH Resp. to Mot., at 2–4. In Cardinal Health's view, Appellant's claims are moot because the drugs purchased for his execution in 2021 have expired, and his entire case is now moot because Cardinal Health "does not know NDOC's current stock of medicines" that may be used in Mr. Floyd's execution. *See id.* Critically, ***Cardinal Health does not deny selling the drugs to NDOC***—indeed it cannot deny such a statement—and

---

on the merits by a court of justice; capable of being disposed of judicially") (emphasis added).

instead asserts Mr. Floyd "assumes without foundation that the medicines were purchased by NDOC from Cardinal Health." [3] *Id.* at 3. If the Court is inclined to entertain Cardinal Health's new arguments, and to avoid any confusion as to source of the drugs, Mr. Floyd has attached copies of the Cardinal Health invoices as **Exhibit A** to this Reply.

Ultimately, each of Cardinal Health's arguments illustrate why this case is not moot because the claims at issue are "capable of repetition, yet evading review." *Bisch v. Las Vegas Metro. Police Dep't*, 129 Nev. 328, 334–35, 302 P.3d 1108, 1113 (2013). NDOC has *once again* obtained execution drugs from Cardinal Health for use in Mr. Floyd's execution, and as Cardinal Health appears to concede, the timeframe for the expiration of the drugs is shorter than a typical legal proceeding. *See* **Exhibit A** to CH's Resp. to Mot. (identifying drug expiration deadlines). If this appeal is dismissed on the basis of mootness—after the issues have

[3] Mr. Floyd's counsel in his § 1983 case has received copies of invoices from NDOC's counsel demonstrating NDOC purchased the new drugs from Cardinal Health. *See* **Exhibit A** to Reply; *see also* R 133 at ¶ 12–13 ("Defendant affirms that all drugs purchased by NDOC for purposes of any execution have been purchased through the Cardinal Health online purchase portal, and in the same manner in which NDOC purchases all of its drugs").

been fully brief, argued, and submitted for decision—Mr. Floyd must re-litigate these same issues each time a new round of drugs is purchased, and each round of new drugs purchased for his execution will likely expire before the issues reach this Court. As a result, Mr. Floyd's claims are not moot because they, in part, rely upon drugs that have relatively short shelf-lives, there is a likelihood these issues will arise (and already have arisen) again, and this case involves important questions, and thus capable of repetition but evading review.

Accordingly, Appellant respectfully requests that the Court take judicial notice of the Status Report in the event it is inclined to consider the issue of mootness.[4]

DATED this 4th day of March, 2024.

BY: *_/s/ Marian L. Massey, Esq._*
MARIAN L. MASSEY, ESQ.
Nevada Bar No. 14579
TALG, NV, Ltd.
5852 S. Durango Drive, Ste. 105
Las Vegas, Nevada 89113
Pro Bono Attorney for Appellant

[4] Cardinal Health also asserts that Mr. Floyd has only sought declaratory and injunctive relief in this matter. *See* CH Response to Mot., at 1. This misconstrues the damages pleaded in Appellant's Complaint and associated with Mr. Floyd's causes of action against Cardinal Health for Breach of Contract and Negligent Performance of an Undertaking. *See* R 18 at ¶ 496; *see* R 19 at ¶ 50.

CERTIFICATE OF SERVICE

This is to certify that on March 4, 2024, a true and correct copy of the foregoing **APPELLANT'S REPLY TO CARDINAL HEALTH'S RESPONSE TO MOTION FOR LEAVE TO FILE REQUEST TO TAKE JUDICIAL NOTICE** was served on the following by United States Mail, first class, and by the Nevada Supreme Court Electronic Filing System:

Steve Morris
Rosa Solis-Rainey
Morris Law Group
801 South Rancho Drive, Ste. B4
Las Vegas, NV 89106
Attorneys for Respondent Cardinal Health, Inc.

Pro Bono Project
Legal Aid Center of Southern Nevada
725 E. Charleston Blvd.
Las Vegas, NV 89104

Aaron D. Ford
Chris Davis
Deputy Attorney General
555 E. Washington Ave., Ste. 3900
Las Vegas, Nevada 89101
Attorneys for Respondent NDOC

Kelly Dove
Co-chair of Pro Bono Committee
Appellate Section of State Bar of Nevada
Snell & Wilmer, LLP
3883 Howard Hughes Parkway, Ste. 1100
Las Vegas, Nevada 89169

BY: */s/ Kavita Narh*
An employee of TALG, NV, Ltd.

EXHIBIT A

EXHIBIT A

CardinalHealth™

CARDINAL HEALTH 110, LLC-PHOENIX
600 NORTH 83RD AVE
TOLLESON AZ 85353-9257

NOT FINAL INVOICE

CUSTOMER SERVICE (800) 926-3161

FED ID 680158739
DEA [redacted]
STATE REG W000569

ROUTE/STOP 019_312/7
INVOICE DATE 02/13
PO 02122024
ORDER DATE 02/12

LL TO 2057199753
/ DEPT OF CORRECTION CTR PHCY
ENTRAL PHCY
955 W RUSSELL RD-CASA GRANDE
AS VEGAS NV 89118
LN [redacted]

SHIP TO 2057199753
NV DEPT OF CORRECTION CTR PHCY
CENTRAL PHCY
3955 W RUSSELL RD-CASA GRANDE
LAS VEGAS NV 89118
GLN [redacted]

DEA [redacted]
STATE REG CA00001
ST CNTLD EXEMPT

LINE	ITEM	NDC/UPC	ORIG ORDER QTY	ORDER QTY	INVOICED QTY	OMIT CODE	UOM	DESCRIPTION	SIZE	FORM	CLASS	MSG	DEPT/ACC/CC2
			TOTE [redacted]	DLVRY [redacted]									
10	[redacted]	[redacted]	3	3	3		CT	KETAMINE MD 50MG/ML 10X10ML C3	10X10	MD	3N		

NOTE CODES

CT	CONTRACT
CO	CT OVERRIDE
CN	CT NET
CS	CT SOURCE
CB	CT SRC BACKUP
NT	NET PRICED
C+	BASE PRICE
OV	OVERRIDE
T	TAXABLE

OMIT CODES

1	RESTRICTED CODE
2	DC DISCONTINUED
3	MFG DISCONTINUED
4	DROP SHIP
5	AVAILABILITY ISSUE
5A	NEW ITEM
5B	NON STOCK
6	TEMP OUT

CHEMICAL DESIGNATIONS

E EPHEDRINE, P PHENYLPROPANOLAMINE

NON-WHOLESALE CUSTOMERS ARE FINAL DISPENSERS THAT ARE PURCHASING FOR THEIR OWN USE AND WILL NOT REDISTRIBUTE PRESCRIPTION PHARMACEUTICALS TO ANY OTHER ENTITY. DSCSA TRANSACTION DATA FOR QUALIFIED PRESCRIPTION DRUGS CAN BE ACCESSED VIA YOUR USUAL ORDERING PLATFORM, SUCH AS ORDER EXPRESS OR MED ECOMMERCE, OR AT CARDINALHEALTH.COM/TRACE®.

IN THE ABSENCE OF A WRITTEN AGREEMENT BETWEEN YOU AND CARDINAL HEALTH 110, LLC, CARDINAL HEALTH 112, LLC THAT GOVERNS THE TRANSACTIONS ON THIS DOCUMENT, THE TERMS AND CONDITIONS LOCATED AT HTTP://WWW.CARDINALHEALTH.COM/EN/SUPPORT/PURCHASE-TERMS-AND-CONDITIONS .HTML WILL APPLY, AND SUCH TERMS AND CONDITIONS MAY NOT BE ALTERED, SUPPLEMENTED, OR AMENDED BY YOU IN ANY WAY.

IF THIS DOCUMENT REFLECTS ANY DISCOUNTED PRICES, CREDITS, OR REBATES, OR IF PRICE REDUCTIONS ARE SUBSEQUENTLY EARNED AND PAID WITH RESPECT TO THE MERCHANDISE/SERVICES DESCRIBED HEREIN, YOU MAY HAVE AN OBLIGATION UNDER FEDERAL OR STATE LAW TO REPORT THE NET COST YOU PAID FOR THE APPLICABLE ITEM IF YOU PARTICIPATE IN CERTAIN FEDERAL OR STATE HEALTHCARE PROGRAMS.

FOR SDS VISIT : HTTP://WWW.MYCARDINALSDSPD.COM

N

REMITTANCE
CARDINAL HEALTH 110, LLC
PO Box 56412
Los Angeles CA 90074-6412
Please remit your payment ad
remits@cardinalhealth.com

PAYMENT TERMS
Net 30 Days

CardinalHealth™

CARDINAL HEALTH 110, LLC-PHOENIX
600 NORTH 83RD AVE
TOLLESON AZ 85353-9257

NOT FINAL INVOICE

CUSTOMER SERVICE (800) 926-3161

FED ID 680158739
DEA [redacted]
STATE REG W000569

ROUTE/STOP 019_312/7
INVOICE DATE 02/13/
PO 02122024a
ORDER DATE 02/12

L TO 2057199753
' DEPT OF CORRECTION CTR PHCY
NTRAL PHCY
55 W RUSSELL RD-CASA GRANDE
S VEGAS NV 89118
.N [redacted]

SHIP TO 2057199753
NV DEPT OF CORRECTION CTR PHCY
CENTRAL PHCY
3955 W RUSSELL RD-CASA GRANDE
LAS VEGAS NV 89118
GLN [redacted]

DEA [redacted]
STATE REG CA00001
ST CNTLD EXEMPT

INE	ITEM	NDC/UPC	ORIG ORDER QTY	ORDER QTY	INVOICED QTY	OMIT CODE	UOM	DESCRIPTION	SIZE	FORM	CLASS	MSG	DEPT/ACC/CC2
			TOTE[redacted]	DLVRY [redacted]									
10	[redacted]	[redacted]	2	2	2		CT	POTASSIUM CL SD 2MEQ/ML 25X10ML	25X10 SD				

NOTE CODES

CT CONTRACT
CO CT OVERRIDE
CN CT NET
CS CT SOURCE
CB CT SRC BACKUP
NT NET PRICED
C+ BASE PRICE
OV OVERRIDE
T TAXABLE

OMIT CODES

1 RESTRICTED CODE
2 DC DISCONTINUED
3 MFG DISCONTINUED
4 DROP SHIP
5 AVAILABILITY ISSUE
5A NEW ITEM
5B NON STOCK
6 TEMP OUT

CHEMICAL DESIGNATIONS

E EPHEDRINE, P PHENYLPROPANOLAMINE
S PSEUDOEPHEDRINE, L OTHER LIST CHEMICAL

NON-WHOLESALE CUSTOMERS ARE FINAL DISPENSERS THAT ARE PURCHASING FOR THEIR OWN USE AND WILL NOT REDISTRIBUTE PRESCRIPTION PHARMACEUTICALS TO ANY OTHER ENTITY. DSCSA TRANSACTION DATA FOR QUALIFIED PRESCRIPTION DRUGS CAN BE ACCESSED VIA YOUR USUAL ORDERING PLATFORM, SUCH AS ORDER EXPRESS OR MED ECOMMERCE, OR AT CARDINALHEALTH.COM/TRACE®.

IN THE ABSENCE OF A WRITTEN AGREEMENT BETWEEN YOU AND CARDINAL HEALTH 110, LLC, CARDINAL HEALTH 112, LLC THAT GOVERNS THE TRANSACTIONS ON THIS DOCUMENT, THE TERMS AND CONDITIONS LOCATED AT HTTP://WWW.CARDINALHEALTH.COM/EN/SUPPORT/PURCHASE-TERMS-AND-CONDITIONS .HTML WILL APPLY, AND SUCH TERMS AND CONDITIONS MAY NOT BE ALTERED, SUPPLEMENTED, OR AMENDED BY YOU IN ANY WAY.

IF THIS DOCUMENT REFLECTS ANY DISCOUNTED PRICES, CREDITS, OR REBATES, OR IF PRICE REDUCTIONS ARE SUBSEQUENTLY EARNED AND PAID WITH RESPECT TO THE MERCHANDISE/SERVICES DESCRIBED HEREIN, YOU MAY HAVE AN OBLIGATION UNDER FEDERAL OR STATE LAW TO REPORT THE NET COST YOU PAID FOR THE APPLICABLE ITEM IF YOU PARTICIPATE IN CERTAIN FEDERAL OR STATE HEALTHCARE PROGRAMS.

FOR SDS VISIT : HTTP://WWW.MYCARDINALSDSPD.COM

N

REMITTANCE
CARDINAL HEALTH 110, LLC
PO Box 56412
Los Angeles CA 90074-6412
Please remit your payment adv
remits@cardinalhealth.com

PAYMENT TERMS
Net 30 Days

CardinalHealth™

CARDINAL HEALTH 110, LLC-PHOENIX
600 NORTH 83RD AVE
TOLLESON AZ 85353-9257

NOT FINAL INVOICE

CUSTOMER SERVICE (800) 926-3161

FED ID 680158739
DEA [redacted]
STATE REG W000569

ROUTE/STOP 019_312/7
INVOICE DATE 02/13/
PO 02122024
ORDER DATE 02/12

DEA [redacted]
STATE REG CA00001
ST CNTLD EXEMPT

.L TO 2057199753
DEPT OF CORRECTION CTR PHCY
NTRAL PHCY
55 W RUSSELL RD-CASA GRANDE
S VEGAS NV 89118
.N [redacted]

SHIP TO 2057199753
NV DEPT OF CORRECTION CTR PHCY
CENTRAL PHCY
3955 W RUSSELL RD-CASA GRANDE
LAS VEGAS NV 89118
GLN [redacted]

INE	ITEM	NDC/UPC	ORIG ORDER QTY	ORDER QTY	INVOICED QTY	OMIT CODE	UOM	DESCRIPTION	SIZE	FORM	CLASS	MSG	DEPT/ACC/CC2
			TOTE [redacted]	DLVRY [redacted]									
10	[redacted]	[redacted]	3	3	3		CT	KETAMINE MD 50MG/ML 10X10ML C3	10X10	MD	3N		

FEB 13 2024

NOTE CODES

CT CONTRACT
CO CT OVERRIDE
CN CT NET
CS CT SOURCE
CB CT SRC BACKUP
NT NET PRICED
C+ BASE PRICE
OV OVERRIDE
T TAXABLE

OMIT CODES

1 RESTRICTED CODE
2 DC DISCONTINUED
3 MFG DISCONTINUED
4 DROP SHIP
5 AVAILABILITY ISSUE
5A NEW ITEM
5B NON STOCK
6 TEMP OUT

CHEMICAL DESIGNATIONS

E EPHEDRINE, P PHENYLPROPANOLAMINE
S PSEUDOEPHEDRINE, L OTHER LIST CHEMICAL

NON-WHOLESALE CUSTOMERS ARE FINAL DISPENSERS THAT ARE PURCHASING FOR THEIR OWN USE AND WILL NOT REDISTRIBUTE PRESCRIPTION PHARMACEUTICALS TO ANY OTHER ENTITY. DSCSA TRANSACTION DATA FOR QUALIFIED PRESCRIPTION DRUGS CAN BE ACCESSED VIA YOUR USUAL ORDERING PLATFORM, SUCH AS ORDER EXPRESS OR MED ECOMMERCE, OR AT CARDINALHEALTH.COM/TRACE*.

IN THE ABSENCE OF A WRITTEN AGREEMENT BETWEEN YOU AND CARDINAL HEALTH 110, LLC, CARDINAL HEALTH 112, LLC THAT GOVERNS THE TRANSACTIONS ON THIS DOCUMENT, THE TERMS AND CONDITIONS LOCATED AT HTTP://WWW.CARDINALHEALTH.COM/EN/SUPPORT/PURCHASE-TERMS-AND-CONDITIONS .HTML WILL APPLY, AND SUCH TERMS AND CONDITIONS MAY NOT BE ALTERED, SUPPLEMENTED, OR AMENDED BY YOU IN ANY WAY.

IF THIS DOCUMENT REFLECTS ANY DISCOUNTED PRICES, CREDITS, OR REBATES, OR IF PRICE REDUCTIONS ARE SUBSEQUENTLY EARNED AND PAID WITH RESPECT TO THE MERCHANDISE/SERVICES DESCRIBED HEREIN, YOU MAY HAVE AN OBLIGATION UNDER FEDERAL OR STATE LAW TO REPORT THE NET COST YOU PAID FOR THE APPLICABLE ITEM IF YOU PARTICIPATE IN CERTAIN FEDERAL OR STATE HEALTHCARE PROGRAMS.

FOR SDS VISIT : HTTP://WWW.MYCARDINALSDSPD.COM

NI

REMITTANCE
CARDINAL HEALTH 110, LLC
PO Box 56412
Los Angeles CA 90074-6412
Please remit your payment ad
remits@cardinalhealth.com

PAYMENT TERMS
Net 30 Days

CardinalHealth™

CARDINAL HEALTH 110, LLC-PHOENIX
600 NORTH 83RD AVE
TOLLESON AZ 85353-9257

NOT FINAL INVOICE

CUSTOMER SERVICE (800) 926-3161

FED ID 680158739
DEA [redacted]
STATE REG W000569

ROUTE/STOP 019_312/7
INVOICE DATE 02/13
PO 02122024a
ORDER DATE 02/1

ILL TO 2057199753
V DEPT OF CORRECTION CTR PHCY
ENTRAL PHCY
955 W RUSSELL RD-CASA GRANDE
AS VEGAS NV 89118
LN [redacted]

SHIP TO 2057199753
NV DEPT OF CORRECTION CTR PHCY
CENTRAL PHCY
3955 W RUSSELL RD-CASA GRANDE
LAS VEGAS NV 89118
GLN [redacted]

DEA [redacted]
STATE REG CA00001
ST CNTLD EXEMPT

LINE	ITEM	NDC/UPC	ORIG ORDER QTY	ORDER QTY	INVOICED QTY	OMIT CODE	UOM	DESCRIPTION	SIZE	FORM	CLASS	MSG	DEPT/ACC/CC2
			TOTE[redacted]	DLVRY [redacted]									
10	[redacted]	[redacted]	2	2	2		CT	POTASSIUM CL SD 2MEQ/ML 25X10ML	25X10 SD				

FEB 13 2024

NOTE CODES

CT CONTRACT
CO CT OVERRIDE
CN CT NET
CS CT SOURCE
CB CT SRC BACKUP
NT NET PRICED
C+ BASE PRICE
OV OVERRIDE
T TAXABLE

OMIT CODES

1 RESTRICTED CODE
2 DC DISCONTINUED
3 MFG DISCONTINUED
4 DROP SHIP
5 AVAILABILITY ISSUE
5A NEW ITEM
5B NON STOCK
6 TEMP OUT

CHEMICAL DESIGNATIONS

E EPHEDRINE, P PHENYLPROPANOLAMINE
S PSEUDOEPHEDRINE, L OTHER LIST CHEMICAL

NON-WHOLESALE CUSTOMERS ARE FINAL DISPENSERS THAT ARE PURCHASING FOR THEIR OWN USE AND WILL NOT REDISTRIBUTE PRESCRIPTION PHARMACEUTICALS TO ANY OTHER ENTITY. DSCSA TRANSACTION DATA FOR QUALIFIED PRESCRIPTION DRUGS CAN BE ACCESSED VIA YOUR USUAL ORDERING PLATFORM, SUCH AS ORDER EXPRESS OR MED ECOMMERCE, OR AT CARDINALHEALTH.COM/TRACE®.

IN THE ABSENCE OF A WRITTEN AGREEMENT BETWEEN YOU AND CARDINAL HEALTH 110, LLC, CARDINAL HEALTH 112, LLC THAT GOVERNS THE TRANSACTIONS ON THIS DOCUMENT, THE TERMS AND CONDITIONS LOCATED AT HTTP://WWW.CARDINALHEALTH.COM/EN/SUPPORT/PURCHASE-TERMS-AND-CONDITIONS .HTML WILL APPLY, AND SUCH TERMS AND CONDITIONS MAY NOT BE ALTERED, SUPPLEMENTED, OR AMENDED BY YOU IN ANY WAY.

IF THIS DOCUMENT REFLECTS ANY DISCOUNTED PRICES, CREDITS, OR REBATES, OR IF PRICE REDUCTIONS ARE SUBSEQUENTLY EARNED AND PAID WITH RESPECT TO THE MERCHANDISE/SERVICES DESCRIBED HEREIN, YOU MAY HAVE AN OBLIGATION UNDER FEDERAL OR STATE LAW TO REPORT THE NET COST YOU PAID FOR THE APPLICABLE ITEM IF YOU PARTICIPATE IN CERTAIN FEDERAL OR STATE HEALTHCARE PROGRAMS.

FOR SDS VISIT : HTTP://WWW.MYCARDINALSDSPD.COM

NO

REMITTANCE
CARDINAL HEALTH 110, LLC
PO Box 56412
Los Angeles CA 90074-6412
Please remit your payment ad
remits@cardinalhealth.com

PAYMENT TERMS
Net 30 Days

Order Status

Print |

Confirmation #: [redacted]
Order Status: In Process
Sales Order #: [redacted]
PO #: 02122024a
Order Date: 02/12/2024 4:29 PM
PO Memo: Not Available
Customer #: [redacted]
Customer Name: NV DEPT OF CORRECTION CTR PHCY
Order Type: REGULAR

ORDER QTY	EXPECTED SHIPPED QTY	SHIPPED QTY	BACKORDER QTY	SUB	CIN	NDC/UPC	TRADE NAME GENERIC NAME	MFR	STRENGTH	FORM	SIZE	TYPE	CONTRACT	COST	TOTAL COST
2	2	TBD	0		[redacted]	[redacted]	POTASSIUM CHLORIDE POTASSIUM CHLORIDE	[redacted]	2MEQ/ML	SDV	25x10 ML	Rx		$457.74	TBD

Sales Order Total

Lines:1 **TBD**

NDOC 02132024-5

Product Details

Generic Name:	POTASSIUM CHLORIDE
Description:	POTASSIUM CL SD 2MEQ/ML 25X10ML
CIN:	[redacted]
NDC:	[redacted]
UPC:	[redacted]
Contract:	
Contract Alias:	
Contract Expires:	
Strength:	2MEQ/ML
Form:	SINGLEDOSE VIAL
Size:	25X10 ML
AB Rating:	AP
Stock Status:	**Stocked**
Quantity Available to Order at this time:	12
Confirmed Order Quantity:	
Notes:	

Invoice Cost:	$ 457.74
Estimated Rebate:	0.0%
Estimated Net Cost:	$457.74
UOI Cost:	$18.3096
Previously Purchased:	
AMU:	
ABC Ranking:	
MIN Qty:	0
MAX Qty:	0

Quantity:

☐ Do not substitute

NDOC 02132024-10

Product Details
Alternatives and Substitutes

PRODUCT INFORMATION	COST & STOCK INFORMATION	REFERENCE INFORMATION
Generic/Brand Indicator: 1	**Retail Price:** $ 488.00	**Additional Attributes:**
Label Size: 25X10ML	**Price Last Changed:** 02/03/2024	**Additional Description:**
Mfr: [redacted] INC	**Retail Price Override:**	**AHFS Code:** [redacted]
Mfr Part #:	**Returnable:** Y	**AHFS Description:** REPLACEMENT PREPARATIONS
Product Type: Rx	**AWU:**	**DAPA #:**
Specialty: N	**Cardinal Key:** [redacted]	**DEA Schedule:** 0
CSN:	**GCN:** [redacted]	**Desi Indicator:** Non-drug and other non-applicable items
UDF1:	**Other CIN(s):**	**FDB Manuf/Dist Name:** [redacted]
UDF2:	**Package Qty:** 25	**FDB Label Name:** POTASSIUM CL 20 MEQ/10 ML CONC
UOI Factor: 25.0000	**Package Size:** 10	**FDB Flavor Desc:**
Category Code 1:	**Return Packaging:** Ambient	**FDB Shape:**
Category Code 2:	**Total Size:** 250	**FDB Color:** colorless
MIN Qty: 0 **Override:** ☐	**Unit Dose:**	**FDB Additional Descriptor:** SUV, OUTER
MAX Qty: 0 **Override:** ☐	**Unit of Sale:** CAN	**Fineline Code:** 8500
Projected Monthly Usage:	**Unit of Measure:** ML	**Fineline Desc:** Pharmaceuticals
Projected Usage Expires:		**HCPCS:** [redacted]
On Formulary: ☐		**Medispan AWP:** $480.00
Message Text:		**Medispan GPI Code:** [redacted]
Never Sub: ☐		**Ingredients:** View

NDOC 02132024 -7

Order Status

Print |

Confirmation #: [redacted]
Order Status: In Process
Sales Order #: [redacted]
Order Date: 02/12/2024 3:07 PM
Customer #: [redacted]
Order Type: REGULAR

PO #: 02122024
PO Memo: Not Available
Customer Name: NV DEPT OF CORRECTION CTR PHCY

ORDER QTY	EXPECTED SHIPPED QTY	SHIPPED QTY	BACKORDER QTY	SUB	CIN	NDC/UPC	TRADE NAME GENERIC NAME	MFR	STRENGTH	FORM	SIZE	TYPE	CONTRACT	COST	TOTAL COST
3	3	TBD	0		[redacted]	[redacted]	KETAMINE HCL KETAMINE HCL	[redacted]	50MG/ML	MDV	10x10 ML	C3		$133.67	TBD

Sales Order Total

Lines:**1** **TBD**

NDOC 02132024-8

Product Details

Generic Name:	KETAMINE HCL
Description:	KETAMINE MD 50MG/ML 10X10ML C3
CIN:	[redacted]
NDC:	[redacted]
UPC:	[redacted]
Contract:	
Contract Alias:	
Contract Expires:	
Strength:	50MG/ML
Form:	MULTI DOSE VIAL
Size:	10X10 ML
AB Rating:	AP
Stock Status:	**Stocked**
Quantity Available to Order at this time:	3
Confirmed Order Quantity:	
Notes:	

Invoice Cost:	$ 133.67
Estimated Rebate:	0.0%
Estimated Net Cost:	$133.67
UOI Cost:	$13.3670
Previously Purchased:	
AMU:	
ABC Ranking:	
MIN Qty:	0
MAX Qty:	0

Quantity: ____

☐ Do not substitute

Printed
2:09 pm
2/12/24

NDOC 02132024-9

Product Details
Alternatives and Substitutes

PRODUCT INFORMATION	COST & STOCK INFORMATION	REFERENCE INFORMATION
Generic/Brand Indicator: 1	**Retail Price:** $ 115.90	**Additional Attributes:**
Label Size: 10X10ML	**Price Last Changed:** 02/01/2024	**Additional Description:**
Mfr: [redacted]	**Retail Price Override:**	**AHFS Code:** [redacted]
Mfr Part #:	**Returnable:** Y	**AHFS Description:** GENERAL ANESTHETICS, MISCELLANEOUS
Product Type: C3	**AWU:**	**DAPA #:**
Specialty: N	**Cardinal Key:** [redacted]	**DEA Schedule:** 7
CSN:	**GCN:** [redacted]	**Desi Indicator:** Non-drug and other non-applicable items
UDF1:	**Other CIN(s):**	**FDB Manuf/Dist Name:** [redacted]
UDF2:	**Package Qty:** 10	**FDB Label Name:** KETAMINE 500 MG/10 ML VIAL
UOI Factor: 10.0000	**Package Size:** 10	**FDB Flavor Desc:**
Category Code 1:	**Return Packaging:** Ambient	**FDB Shape:**
Category Code 2:	**Total Size:** 100	**FDB Color:** colorless
MIN Qty: 0 **Override:** ☐	**Unit Dose:**	**FDB Additional Descriptor:** MUV
MAX Qty: 0 **Override:** ☐	**Unit of Sale:** CAN	**Fineline Code:** [redacted]
Projected Monthly Usage:	**Unit of Measure:** ML	**Fineline Desc:** Pharmaceuticals
Projected Usage Expires:		**HCPCS:**
On Formulary: ☐		**Medispan AWP:** $114.00
Message Text:		**Medispan GPI Code:** [redacted]
Never Sub: ☐		**Ingredients:** View

NDOC 02132024 - 10